Alentis’ ALE.C04 receives fast track designation from FDA

Alentis’ ALE.C04 receives fast track designation from FDA

Submitted by admin on August 25, 2023 - 9:44am
Source: 
Pharmaceutical Business Review
News Tags: 
Alentis Therapeutics
FDA
ALE.C04
metastatic head and neck squamous cell carcinoma
head and neck cancer
Headline: 
Alentis’ ALE.C04 receives fast track designation from FDA
snippet: 


Alentis Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for its antibody ALE.C04 to treat patients with recurrent or metastatic, CLDN1-positive head and neck squamous cell carcinoma (HNSCC).

Do Not Allow Advertisers to Use My Personal information